A detailed history of Cibc World Markets Corp transactions in Exelixis, Inc. stock. As of the latest transaction made, Cibc World Markets Corp holds 19,669 shares of EXEL stock, worth $435,668. This represents 0.0% of its overall portfolio holdings.

Number of Shares
19,669
Holding current value
$435,668
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$20.17 - $23.93 $396,723 - $470,679
19,669 New
19,669 $466,000
Q2 2021

Aug 10, 2021

SELL
$17.95 - $25.56 $601,325 - $856,260
-33,500 Closed
0 $0
Q1 2021

May 07, 2021

BUY
$20.53 - $25.22 $687,755 - $844,870
33,500 New
33,500 $757,000
Q1 2018

May 11, 2018

SELL
$22.15 - $31.89 $5.3 Million - $7.62 Million
-239,100 Closed
0 $0
Q4 2017

Feb 13, 2018

BUY
$24.23 - $30.93 $5.79 Million - $7.4 Million
239,100
239,100 $7.27 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $7.13B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Cibc World Markets Corp Portfolio

Follow Cibc World Markets Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cibc World Markets Corp, based on Form 13F filings with the SEC.

News

Stay updated on Cibc World Markets Corp with notifications on news.